Gain Therapeutics Inc.
07/16/2026 | Press release | Distributed by Public on 07/16/2026 05:53
Material Event (Form 8-K)
Item 8.01. Other Events.
On July 16, 2026, Gain Therapeutics, Inc. (the "Company") issued a press release and shareholder letter in which it announced, among other things, that its current cash and cash equivalents are anticipated to fund the Company's operations into the second quarter of 2027, based on current operating plans, including the completion of the Phase 1b open-label extension in October 2026 and initiation of a Phase 2 clinical study during the third quarter of 2026.
Gain Therapeutics Inc. published this content on July 16, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on July 16, 2026 at 11:54 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]